Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended September 30th, 2026. The business recorded highest quarterly sales with a solid growth of 12% YoY. The company delivered global revenue of INR 7,404 Cr with a sequential growth of 4% QoQ, while EBITDA margin expanded by 200 basis points QoQ to 18.7%.

One India Business

The One India business grew at a solid 12% YoY. Branded Prescription business delivered robust growth, with key therapies outpacing the market. The Trade Generics business delivered a strong double-digit QoQ growth. Consumer Health anchor brands maintained leadership positions in their respective market segments.

North America

The U.S. business posted revenue of $172 Mn during the quarter, continuing its sequential growth trajectory. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market, with a 22% market share. The business entered an exclusive partnership with Qilu Pharmaceutical for the commercialization of a Keytruda biosimilar.

One Africa

In South Africa Private Market, secondary growth was at 6.5% versus the market growth of 5.0%. The prescription business maintained its No.2 position.

As a result, Cipla Limited continues to focus on sustained growth in its core businesses, improving productivity, and strengthening its pipeline to serve patients with trusted, high-quality medicines. We expect the upcoming product pipeline to support continued performance in North America.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Cipla Limited

Cipla Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Cipla moves sideways over three months, with neither buyers nor sellers taking control. The PEG of 2.77 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 31% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 7.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Cipla Limited.

Onesource Specialty Pharma Limited (NSE: ONESOURCE) announced its consolidated financial results for the quarter ended September 30, 2026, showcasing robust performance with revenue up 37% year-over-year and EBITDA up 53% year-over-year. The company reported revenue of ₹5,162 million, a 37% increase compared to the same quarter last year, and an EBITDA of ₹1,633 million, marking a 53% rise year-over-year. These impressive figures highlight the company’s strong operational leverage and strategic growth initiatives.

Revenue and EBITDA Growth

The revenue of ₹5,162 million reflects a 37% year-over-year increase and a 15% quarter-over-quarter increase. This growth is driven by the new DDC (drug-device combination) capacity, robust MSA (Master Service Agreement) execution, and multiple product launches across all business segments. The EBITDA of ₹1,633 million shows a 53% year-over-year increase and a 32% quarter-over-quarter increase, with margins expanding to 32%, driven by operating leverage from higher volumes across the business.

Adjusted PAT and EPS

The adjusted PAT stood at ₹937 million, with an adjusted EPS of ₹8.2, showing a 109% year-over-year increase. This significant growth is supported by the company’s strategic initiatives and operational efficiencies. The adjusted figures exclude exceptional items and scheme-related intangible amortization.

Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, commented, “Q2 delivered strong sequential growth, led by new DDC capacity. With our second cartridge line commercial, H2 will see new launches and a significant ramp-up in commercial volumes. Biologics momentum remained strong, with yet another US biotech onboarded during the quarter. With additional capacity and partnerships, we are well set for the next phase of growth.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Onesource falls 14.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 30, well into oversold territory. Yet sellers still dominated on 17 of recent sessions versus 13 for buyers, so the pressure has not fully lifted. Revenue grows at 232.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 14.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Onesource Specialty Pharma Limited.

Mankind Pharma Limited (NSE: MANKIND) announced its financial results for the second quarter and half year ended 30th September 2026, showcasing a robust performance. The company reported a strong revenue growth of 17% year-on-year, with an EBITDA increase of 27% and a PAT surge of 38%. The disciplined execution and strengthening business fundamentals have driven this impressive performance.

Strong Domestic Business Growth

The domestic business delivered robust growth of 16%, led by a 1.2x volume outperformance to IPM. This was further supported by mid-teen growth in Mankind Domestic with 1.1x chronic outperformance, driven by growth of 19% in Cardiac and 16% in Anti-diabetes. Acute outperformance of 1.1x was led by 19% growth in Gastro and 26% in VMN. Steady double-digit growth was observed in BSV domestic specialty business.

International Business Expansion

The international business grew by 33%, while the OTC segment witnessed muted growth in Q2. The company’s recent acquisition of Armed Cell Therapeutics marks a strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth.

As a result, Mankind Pharma Limited continues to maintain its #1 rank over the last 9 years with a prescription share of 15.2% and prescriber penetration of 84.4% in MAT August’26.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Mankind Pharma Limited

Mankind Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Mankind falls 8.4% over three months and has not found a floor yet. The PEG reaches 3.22. The stock trades on brand and index weight, not on growth. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gains 1.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 17.7% and profits at 14.3% CAGR, with D/E of 0.58. Meanwhile, the stock dips 8.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Mankind Pharma Limited.